Ingo Hartung is heading Medicinal Chemistry GER at Merck Healthcare KGaA since 2019. He is an experienced medicinal chemist with a demonstrated history of successfully driving projects into clinical development in cardiology and oncology and steering project portfolios. He is especially interested in innovative NCE modalities, such as protein degraders and modulators of RNA function, and lead finding technologies for difficult-to-drug targets. Ingo is chairing the DECHEMA natural product working group and is a SAB member of ChemMedChem and the Chemical Probes Portal.